Sutent is an oral multi-kinase inhibitor approved for the treatment of advanced RCC(renal cell carcinoma) and GIST(gastrointestinal stromal tumor) after disease progression on or intolerance to imatinib mesylate(Gleevec).
An independent Data Monitoring Committee (DMC) recommended halting the trial after concluding that Sutent demonstrated greater progression-free survival compared to placebo plus best supportive care in patients with pancreatic islet cell tumors.
This phase 3 trial of sunitinib in patients with advanced pancreatic islet cell tumors was initiated based on the results of a earlier phase 2 trial.
Sutent is currently approved for both advanced renal cell carcinoma (RCC) and second-line gastrointestinal stromal tumor (GIST), based on efficacy and safety data from large, randomized phase 3 clinical trials.
Sutent has played an important role in reshaping the treatment landscape for RCC and GIST. More than 38,000 patients globally have been treated with Sutent in the clinical setting and trials. <헬스코리아뉴스>
저작권자 © 헬스코리아뉴스 무단전재 및 재배포 금지
